BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND TOP2A, TOP2, TP2A AND Treatment
123 results:

  • 1. The correlation study between top2a gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Ye JH; Yu J; Huang MY; Mo YM
    Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Anthracyclines induce cardiotoxicity through a shared gene expression response signature.
    Matthews ER; Johnson OD; Horn KJ; Gutiérrez JA; Powell SR; Ward MC
    PLoS Genet; 2024 Feb; 20(2):e1011164. PubMed ID: 38416769
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
    Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
    BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Risk factors for cancer-related cognitive impairment in breast and colorectal cancer patients who undergo chemotherapy].
    Iranzo P; Callejo A; Arbej J; Menao S; Isla D; Andrés R
    An Sist Sanit Navar; 2023 Aug; 46(2):. PubMed ID: 37594060
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Bioinformatics analysis to identify breast cancer-related potential targets and candidate small molecule drugs.
    Hong H; Chen H; Zhao J; Qin L; Li H; Huo H; Shi S
    Mutat Res; 2023; 827():111830. PubMed ID: 37437506
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Proteomic Dynamics of breast cancer Cell Lines Identifies Potential Therapeutic Protein Targets.
    Sun R; Ge W; Zhu Y; Sayad A; Luna A; Lyu M; Liang S; Tobalina L; Rajapakse VN; Yu C; Zhang H; Fang J; Wu F; Xie H; Saez-Rodriguez J; Ying H; Reinhold WC; Sander C; Pommier Y; Neel BG; Aebersold R; Guo T
    Mol Cell Proteomics; 2023 Aug; 22(8):100602. PubMed ID: 37343696
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. ATM suppresses c-Myc overexpression in the mammary epithelium in response to estrogen.
    Najnin RA; Al Mahmud MR; Rahman MM; Takeda S; Sasanuma H; Tanaka H; Murakawa Y; Shimizu N; Akter S; Takagi M; Sunada T; Akamatsu S; He G; Itou J; Toi M; Miyaji M; Tsutsui KM; Keeney S; Yamada S
    Cell Rep; 2023 Jan; 42(1):111909. PubMed ID: 36640339
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer.
    Kumar U; Castellanos-Uribe M; May ST; Yagüe E
    Gene; 2023 Jan; 850():146930. PubMed ID: 36195266
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of crucial hub genes and potential molecular mechanisms in breast cancer by integrated bioinformatics analysis and experimental validation.
    Yadav DK; Sharma A; Dube P; Shaikh S; Vaghasia H; Rawal RM
    Comput Biol Med; 2022 Oct; 149():106036. PubMed ID: 36096037
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]    [Full Text] [Related]  

  • 12. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
    Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
    Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Screening of differentially expressed genes for colorectal cancer and prediction of potential traditional Chinese medicine: based on bioinformatics].
    Yun ZJ; Wang HJ; Yu YX; Sun ZY; Yao SK
    Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1666-1676. PubMed ID: 35347966
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Autophagy-Dependent Sensitization of Triple-Negative breast cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.
    Tyutyunyk-Massey L; Sun Y; Dao N; Ngo H; Dammalapati M; Vaidyanathan A; Singh M; Haqqani S; Haueis J; Finnegan R; Deng X; Kirberger SE; Bos PD; Bandyopadhyay D; Pomerantz WCK; Pommier Y; Gewirtz DA; Landry JW
    Mol Cancer Res; 2021 Aug; 19(8):1338-1349. PubMed ID: 33811160
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
    Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
    Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and top2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
    Zhu J; Muskhelishvili L; Tong W; Borlak J; Chen M
    Sci Rep; 2020 May; 10(1):8188. PubMed ID: 32424219
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Chromatin regulators mediate anthracycline sensitivity in breast cancer.
    Seoane JA; Kirkland JG; Caswell-Jin JL; Crabtree GR; Curtis C
    Nat Med; 2019 Nov; 25(11):1721-1727. PubMed ID: 31700186
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer.
    Zhou YH; Liu Y; Zhang W; Liu C; He JJ; Tang XJ
    Pathol Res Pract; 2019 Nov; 215(11):152644. PubMed ID: 31551176
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
    Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
    Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.